YS-RD11(YS-RD11) - 药物靶点：α-synuclein_在研适应症：帕金森病_专利_临床

概要

基本信息

药物类型

化学药

别名

靶点

α-synuclein

作用机制

α-synuclein抑制剂(α-突触核蛋白抑制剂)

治疗领域

神经系统疾病内分泌与代谢疾病

在研适应症

帕金森病

非在研适应症-

原研机构

O-Force Co., Ltd

在研机构

O-Force Co., Ltd

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 YS-RD11 相关的临床结果

登录后查看更多信息

100 项与 YS-RD11 相关的转化医学

登录后查看更多信息

100 项与 YS-RD11 相关的专利（医药）

登录后查看更多信息

1

项与 YS-RD11 相关的文献（医药）

Biomolecules

An 11-mer Synthetic Peptide Suppressing Aggregation of Aβ25-35 and Resolving Its Aggregated Form Improves Test Performance in an Aβ25-35-Induced Alzheimer’s Mouse Model

Article

作者: Hayashi, Yoshihiro ; Nakamura, Rina ; Higashi, Youichirou ; Konishi, Motomi ; Akizawa, Toshifumi ; Matsuda, Akira ; Saito, Motoaki

There is a high demand for the development of drugs against Alzheimer’s disease (AD), which is related to the misfolding and aggregation of Amyloid-β (Aβ), due to the increasing number of patients with AD. In our present study, we aimed to assess the aggregation inhibitory effect of various synthetic YS-peptides on Aβ25-35 to identify an applicable peptide for clinical use for AD treatment and prevention. Suppression and aggregate resolution activities of YS-peptides against Aβ25-35 were evaluated using a Thioflavin T assay and scanning electron microscopy (SEM). Structure–activity relationship studies revealed that YS-RD11 (RETLVYLTHLD) and YS-RE16 (RETLVYLTHLDYDDTE) showed suppression and aggregate-resolution activities. The effect of YS-peptides on phagocytosis in microglial cells (BV-2 cells) demonstrated that YS-RD11 and YS-RE16 activated the phagocytic ability of microglia. In the Aβ25-35-induced AD mouse model, YS-RD11 prevented and improved the deficits in short-term memory. In conclusion, YS-RD11 is a suitable candidate therapeutic drug against AD and uses a strategy similar to that used for antibodies.

100 项与 YS-RD11 相关的药物交易

登录后查看更多信息